ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
- Written by PR Newswire
![]() |
- Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment
- Accelerating R&D on core technologies, including expansion of indications for the Grabody platform
SEOUL, South Korea, Dec. 26, 2025 /PRNewswire/ -- ABL Bio (CEO Sang Hoon Lee), a company specializing in...















